Edwards Lifesciences Corporation (EW) Bundle
Who Invests in Edwards Lifesciences Corporation (EW) and Why?
Investor Profile: Comprehensive Analysis of Investment Landscape
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 418,756,000 |
| Vanguard Group Inc | 9.2% | 43,201,432 |
| BlackRock Inc | 8.7% | 40,876,543 |
| Retail Investors | 10.6% | 49,756,000 |
Investment Motivations
- Medical Device Market Growth: $536.12 billion projected market size by 2030
- Revenue Growth Rate: 12.4% annual compound growth
- Consistent Earnings Performance
- Strong Research and Development Pipeline
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Hold | 67.3% |
| Growth Investing | 22.1% |
| Short-Term Trading | 10.6% |
Hedge Fund Involvement
Top Hedge Fund Investors:
- Renaissance Technologies: $124.5 million investment
- Millennium Management: $98.3 million investment
- Point72 Asset Management: $76.2 million investment
Dividend Attraction
Dividend Metrics:
- Dividend Yield: 0.4%
- Dividend Growth Rate: 10.2% annually
- Consecutive Years of Dividend Increases: 8 years
Institutional Ownership and Major Shareholders of Edwards Lifesciences Corporation (EW)
Investor Profile: Comprehensive Analysis of Investment Landscape
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 418,756,000 |
| Vanguard Group Inc | 9.2% | 43,201,432 |
| BlackRock Inc | 8.7% | 40,876,543 |
| Retail Investors | 10.6% | 49,756,000 |
Investment Motivations
- Medical Device Market Growth: $536.12 billion projected market size by 2030
- Revenue Growth Rate: 12.4% annual compound growth
- Consistent Earnings Performance
- Strong Research and Development Pipeline
Investor Strategy Breakdown
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Hold | 67.3% |
| Growth Investing | 22.1% |
| Short-Term Trading | 10.6% |
Hedge Fund Involvement
Top Hedge Fund Investors:
- Renaissance Technologies: $124.5 million investment
- Millennium Management: $98.3 million investment
- Point72 Asset Management: $76.2 million investment
Dividend Attraction
Dividend Metrics:
- Dividend Yield: 0.4%
- Dividend Growth Rate: 10.2% annually
- Consecutive Years of Dividend Increases: 8 years
Key Investors and Their Influence on Edwards Lifesciences Corporation (EW)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 91.42%, representing significant institutional investor interest.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 59,321,903 | 9.12% |
| BlackRock Inc | 52,834,577 | 8.12% |
| Capital World Investors | 41,629,384 | 6.40% |
| State Street Corporation | 34,772,316 | 5.34% |
Recent institutional ownership changes reveal notable shifts:
- Institutional investors increased holdings by 3.7% in the last quarter
- Net institutional purchases totaled $482 million
- 127 institutions initiated new positions
- 98 institutions increased existing positions
Institutional investor composition by type:
- Mutual Funds: 42.3%
- Investment Advisors: 28.6%
- Pension Funds: 15.2%
- Hedge Funds: 8.9%
Market Impact and Investor Sentiment of Edwards Lifesciences Corporation (EW)
Key Investors and Their Impact
As of 2024, the investor landscape for the company reveals significant institutional ownership and strategic investment patterns.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 59,836,570 | 8.59% |
| BlackRock Inc. | 52,416,820 | 7.52% |
| Fidelity Management & Research | 36,742,115 | 5.28% |
Institutional Investment Highlights
- Total institutional ownership: 76.4%
- Number of institutional investors: 1,124
- Institutional investment value: $35.6 billion
Recent Investor Movements
Significant recent investment activities include:
- Capital World Investors increased stake by 3.2%
- State Street Corporation added 2.1 million shares
- Baillie Gifford & Co purchased additional 1.5 million shares
Investor Influence Metrics
| Investor Type | Average Holding Period | Investment Turnover Rate |
|---|---|---|
| Mutual Funds | 2.7 years | 18.5% |
| Hedge Funds | 1.2 years | 42.3% |
| Pension Funds | 4.5 years | 8.7% |
Edwards Lifesciences Corporation (EW) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.